Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-09-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://link.springer.com/article/10.1186/s13045-017-0518-8 |
| _version_ | 1817977532869246976 |
|---|---|
| author | Francine Foss Steven Horwitz Barbara Pro H. Miles Prince Lubomir Sokol Barbara Balser Julie Wolfson Bertrand Coiffier |
| author_facet | Francine Foss Steven Horwitz Barbara Pro H. Miles Prince Lubomir Sokol Barbara Balser Julie Wolfson Bertrand Coiffier |
| author_sort | Francine Foss |
| collection | DOAJ |
| first_indexed | 2024-04-13T22:17:41Z |
| format | Article |
| id | doaj.art-b42cb511fd334b6cb7b849ff3091839e |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-13T22:17:41Z |
| publishDate | 2017-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-b42cb511fd334b6cb7b849ff3091839e2022-12-22T02:27:24ZengBMCJournal of Hematology & Oncology1756-87222017-09-011011210.1186/s13045-017-0518-8Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialFrancine Foss0Steven Horwitz1Barbara Pro2H. Miles Prince3Lubomir Sokol4Barbara Balser5Julie Wolfson6Bertrand Coiffier7Yale Cancer CenterMemorial Sloan-Kettering Cancer CenterKimmel Cancer Center, Thomas Jefferson UniversityPeter MacCallum Cancer Centre, University of MelbourneMoffitt Cancer CenterVeristat, LLCVeristat, LLCHospices Civils de Lyonhttp://link.springer.com/article/10.1186/s13045-017-0518-8 |
| spellingShingle | Francine Foss Steven Horwitz Barbara Pro H. Miles Prince Lubomir Sokol Barbara Balser Julie Wolfson Bertrand Coiffier Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial Journal of Hematology & Oncology |
| title | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_full | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_fullStr | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_full_unstemmed | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_short | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_sort | erratum to romidepsin for the treatment of relapsed refractory peripheral t cell lymphoma prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| url | http://link.springer.com/article/10.1186/s13045-017-0518-8 |
| work_keys_str_mv | AT francinefoss erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT stevenhorwitz erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT barbarapro erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT hmilesprince erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT lubomirsokol erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT barbarabalser erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT juliewolfson erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT bertrandcoiffier erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial |